Allogeneic stem cell transplantation is often complicated by reactivation of herpesviruses. Mesenchymal stem cells (MSC) are immunomodulatory and may be used to treat graft-versus-host disease. We investigated if herpesviruses infect and can be transmitted by MSC, and if MSC suppress immune responses to various infectious agents. Mesenchymal stem cells from healthy seropositive donors were evaluated with polymerase chain reaction for the most common herpesviruses: cytomegalovirus (CMV), herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2, Epstein-Barr virus (EBV) and varicella zoster virus. The cytopathological effect (CPE) was investigated and viral antigens analyzed by immunofluorescence after in vitro exposure to CMV, HSV-1 and EBV. We also studied MSC effect on lymphocyte stimulation induced by various infectious agents. No viral DNA could be detected in MSC isolated from healthy seropositive individuals. However, a CPE was noted and intracellular viral antigens detected after infection in vitro by CMV and HSV-1, but not by EBV. The CMV and HSV-1 infections were productive. Lymphocyte proliferation by herpesviruses, candida mannan and protein A from Staphylococcus aureus was suppressed by MSC. The data indicate that the risk of herpesvirus transmission by transplantation of MSC from healthy seropositive donors is low. However, MSC may be susceptible to infection if infused in a patient with CMV or HSV-1 viremia. MSC transplantation may compromise the host's defense against infectious agents.
Introduction
Transplantation of hematopoietic stem cells from healthy donors ie allogeneic hematopoietic stem cell transplantation (HSCT) can cure several life-threatening hematological disorders. [1] [2] [3] Complications of HSCT include graft-versushost disease (GvHD), recurrence of disease and infections. 4, 5 Viruses from the herpes family, benign in the immunocompetent host, often reactivate in immunosuppressed transplant recipients -sometimes leading to life-threatening infections. 6 Mesenchymal stem cells (MSC) are non-hematopoietic cells, found in the human bone marrow. Mesenchymal stem cells show extensive proliferative capacity in vitro without loss of phenotype and after expansion retain the ability to differentiate into bone, muscle, cartilage, tendon and fat in vitro and in vivo. [7] [8] [9] [10] [11] When MSC are present in mixed lymphocyte cultures, the proliferation of T lymphocytes is impaired. [12] [13] [14] [15] [16] [17] The suppression occurs regardless of the MSC source and includes 'third party' cells, that is MSC obtained from neither stimulator nor responder cell source. 12, 15, 16 The immunomodulating nature of MSC observed in vitro may be of clinical relevance in allogeneic stem cell transplantation. Autologous in vitro culture expanded MSC have been infused in humans intravenously without causing toxicity. 18 In preliminary reports, MSC have been shown to reduce the incidence and severity of GvHD. 19 Infusion of third-party MSC successfully cured a patient's severe therapy-resistant grade IV acute GvHD of gut and liver. 20 MSC may also be used to cure inborn errors of metabolism, such as Hurler's disease. 21 The above-described characteristics make MSC promising candidates for cell therapy. 22 In the present study, we aimed to investigate whether MSC are susceptible to the most common herpesviruses and if MSC carry these viruses: cytomegalovirus (CMV), herpes simplex-1 (HSV-1) and -2 (HSV-2), Epstein-Barr virus (EBV) and varicella zoster virus (VZV) in the healthy seropositive individual. Transplanted MSC containing viruses may cause infection in the host and viral infection of MSC may affect the outcome of the transplantation. Furthermore, MSC may be destroyed by an ongoing herpesvirus infection in the patient. As MSC have immunosuppressive effects, it is possible that MSC infusion decreases the host's response to infections. We therefore studied MSC's effects on lymphocyte proliferative responses to various infectious agents.
Materials and methods
Isolation, ex vivo culture and characterization of human mesenchymal stem cells To isolate human MSC, bone marrow aspirates of 10-20 ml were taken from the iliac crest of healthy donors. The ethics committee at the Karolinska University Hospital approved the study. Mesenchymal stem cells were isolated and cultured as previously described. 12, 23 Briefly, heparinized bone marrow was separated by a 1.073 g/ml Percoll density gradient (Amersham Biosciences, Little Chalfont, UK). Mononuclear cells were collected, washed and re-suspended in human MSC medium consisting of Dulbecco's-modified Eagle's medium (DMEM)-low glucose (Invitrogen, Paisley, Scotland) supplemented with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA) and 1% antibioticantimycotic solution (Life Technologies, Gaithersburg, MD, USA). The cells were plated at 1.6 Â 10 5 cells/cm 2 in culture flasks. The serum lot was selected on the basis of optimal MSC growth with maximal retention of osteogenic, chondrogenic and adipogenic differentiation. 12 When the cultures were near confluence, the cells were detached by treatment with 0.05% trypsin and 0.35 mM ethylenediaminetetra-acetic acid (EDTA) (Invitrogen, Paisley, UK) and re-plated at a density of 4 Â 10 3 cells/cm 2 . For flow cytometry, cells were incubated with conjugated, monoclonal antibodies against CD34, CD14 and CD45 (BD Biosciences, San Jose, CA, USA), CD44 (Immunotech, Marseilles, France), CD29 (Coulter, Miami, FL, USA), CD166 (MCA1926F; Serotec, Oxford, UK), CD105 (Endoglin, clone SN6h; DakoCytomation, Carpinteria, CA, USA), CD73 (BD Bioscinences, San Jose, CA, USA), the CMV receptor CD13 24 (aminopeptidase N; Harlan Sera-Lab, Belton, UK) and the EBV-receptor CD21 25 (DakoCytomation Norden A/S, Glostrup, Denmark). Non-specific fluorescence was determined using equal aliquots of cell preparation incubated with antimouse monoclonal antibodies (BD Biosciences). Finally, the cells were assayed in a flow cytometer and analyzed with Cellquest software (BD Biosciences). The cells expressed CD166, CD150, CD73, CD44 and CD29 but not CD34, CD45 or CD14. 12, 26 Cells stimulated in vitro differentiated to bone, cartilage and adipose. 12 Polymerase chain reaction for detection of viral DNA in donor mesenchymal stem cells compared to serology of the same viruses Polymerase chain reaction (PCR) detection of viral DNA was performed for CMV, HSV-1, HSV-2, EBV and VZV. We selected healthy MSC donors where we had serological data and used accredited serological methods by the Laboratory of Clinical Virology, for the above-mentioned viruses. For each virus 2.5 Â 10 5 MSC or peripheral blood lymphocytes (PBL), were added to lysis buffer (50 mM TrisHCl, 0.5% sodium dodecyl sulfate, 50 mM NaCl pH 7.5) and proteinase K. After incubation, DNA was prepared with phenol:chloroform (1:1). 0 and 5 0 -ggtaccagacggttaacatc-3 0 , 0.1 pmol/ml, Scandinavian Gene Synthesis), distilled water and 2-3 droplets of paraffin oil for the first reaction. In the second reaction we used primers for a 277 bp fragment (5 0 -cactaccagtcatttctatc-3 0 and 5 0 -atgcagaaacacgttgcaca-3 0 , 10 pmol/ml, Scandinavian Gene Synthesis), Taq polymerase (5 U/ml, Applied Biosystems) and distilled water. This second reaction mixture was put below the oil in the tubes with the product from the first reaction. As a positive control we used isolated VZV DNA and as a negative control distilled water. Polymerase chain reaction producs were electrophoresed on a 3% agarose, Tris-borate (TBE)-EDTA gel stained with 1% ethidium bromide in TBE buffer for visualization.
Herpes simplex virus type 1 and herpes simplex virus type 2 polymerase chain reaction. The HSV-1 and HSV-2 PCR were performed exactly as the VZV PCR, but other primers and settings were used. First reaction primers for HSV-1 (5 0 -atcacggtagcccggccgtgtgaca-3 0 and 5 0 -cataccggaacgcacca cac-3 0 , 10 pmol/ml, Scandinavian Gene Synthesis) for a 221 bp fragment of the HSV-1 glycoprotein D gene and second reaction primers for HSV-1 (5 0 -ccataccgaccacacc gacga-3 0 and 5 0 -ggtagttggtcgttcgcgctg-3 0 , 10 pmol/ml, Scandinavian Gene Synthesis) for a 138 bp fragment. First reaction primers for HSV-2 (5 0 -tcagcccatcctccttcggcagta-3 0 and 5 0 -gatctggtactcgaatgtctccg-3 0 , 10 pmol/ml, Scandinavian Gene Synthesis) for a 184 bp fragment of the HSV-2 glycoprotein G gene and second reaction primers for HSV-2 (5 0 -agacgtgcgggtcgtacacg-3 0 and 5 0 -cgcgcggtcccagatcggca-3 0 , 10 pmol/ml, Scandinavian Gene Synthesis) for a 100 bp fragment. As a positive control we used herpesvirions from supernatants of cell cultures, withdrawn in an early stage when cytopathological effect (CPE) was noted. As a negative control we used distilled water.
Infection of mesenchymal stem cells with herpesviruses
Mesenchymal stem cells were diluted in culture medium to 25 Â 10 3 cells/ml. Samples of 0.5 ml were added to 24-well plates and the cells cultured to near confluence. For the EBV experiment, wells were prepared with cover slips on the bottom. Suspensions, 100 ml, of CMV (AD169 strain) and HSV-1 were added to each well, and wells without addition of virus were saved as a control. Determination of virus titers in the suspensions was performed in human fibroblasts and green monkey kidney (GMK) cells, respectively. Multiplicity of infection was 2.5 infectious particles per cell for CMV and 7.5 infectious particles per cell for HSV-1. For EBV infection 500 ml of thawed P3 cells in medium was added to each well. Plates were incubated for 1 h in the case of CMV and HSV-1 and for 3 h for EBV. The cells were washed and 2.0 ml MSC culture medium added to the wells. Aliquots, 200 ml, from CMV-and HSV-1-exposed cells were frozen and repleted with 200 ml of fresh media on day 0 and every 24 h thereafter for 7 days. The EBV plates were handled in a different manner, described below, and the duration of experiments was 8 days.
To determine the infectivity of the frozen P3 cells in medium, PBL were prepared by Ficoll-hypaque gradient separation (1077 g/cm 3 , Axis-Shield PoC AS, Oslo, Norway) for 20 min at 600 g and one million PBL/well was added to 12-well plates. Thereafter 0.5 ml of the P3 solution was added to 0.4 mm transwell inserts (BD Biosciences, Franklin Lakes, NJ, USA). After 3 h incubation the transwell inserts were removed. Cells for PCR detection of EBV DNA and for immunofluorescence were collected at the start of the experiment, after 3 h and on days 3 and 8.
Immunofluorescence against viral proteins and Epstein-Barr virus polymerase chain reaction analysis After 7 days of incubation MSC exposed to CMV and HSV-1 were washed with culture media and thereafter detached by addition of 0.6 ml trypsin. Aliquots of 20 ml MSC were put on microscopy glasses. Epstein-Barr virusexposed MSC were detached and washed as above, on days 3 and 8, and sent for PCR analysis. Cover slips from the wells were removed. Aliquots of P3 solution were also put on glasses. All glasses were fixed with 90% acetone solution. An anti-human immunoglobulin G (IgG) monoclonal was added to CMV-, HSV-1-and EBV-exposed MSC: anti-CMV (concentration 1/80; Pereira, San Fransico, CA, USA), 27 anti-HSV-1/-2 (concentration 1:1, fluorescein isothiocyanate (FITC) conjugated; DPC, Los Angeles, CA, USA) and anti-EBV (concentration 1/80, diluted in phosphate-buffered saline (PBS)). As antibody against EBV, we used a patient serum with high IgG anti-EBV titer, from the Laboratory of Clinical Virology at the Karolinska University Hospital. The patient serum was tried in different dilutions on P3 cells. Glasses were incubated in a humidified chamber with antibodies and thereafter washed in PBS (Unimedic AB, Matfors, Sweden). The anti-CMV and anti-EBV were nonconjugated, so a monoclonal anti-mouse (concentration 1/20, rabbitamouse, FITC conjugated; DakoCytomation Norden A/S) and an anti-human monoclonal (concentration 1/60, rabbitahuman, FITC conjugated; DakoCytomation Norden A/S) were used, respectively. Incubation and washing was performed as above. For the evaluation of the P3 solution we used an anti-CD19 monoclonal (concentration 1/2, phycoerythrin-conjugated (PE); BD Biosciences), to visualize B lymphocytes. Thereafter, glasses were counterstained with Evans blue (final concentration 1:3000 in distilled water) and fixed with glycerol in veronal buffer (pH 8.6).
Titration of frozen supernatants on GMK cells and fibroblasts
Cell lines of GMK cells and fibroblasts were harvested through trypsinization, as above. Cells were diluted in DMEM (Invitrogen) supplemented with 10% FBS (Sigma) to an appropriate concentration and then put in tubes. Tubes were incubated until the cells reached confluence. Thereafter, the medium was changed to DMEM (Invitrogen) with addition of 2% FBS and 0.1 ml sample was inoculated. Inoculated cells were incubated as above. Samples were inoculated from 0, 72 and 144 h for CMV and 0, 24, 48, 72, 144 h for HSV-1. Freezed supernatants were diluted 10-fold in the later medium. Three and four tubes were inoculated from each sample dilution for CMV and HSV-1, respectively. Samples from HSV-1-exposed cells were read in the microscope 1 week later. Cytomegalovirus-exposed samples received new medium 1 week after inoculation and was read after 4 weeks.
Antigen stimulations
Peripheral blood lymphocytes, 1.5 Â 10 5 , were placed in triplicate in flat-bottomed 96-well plates (Nunclone, NUNC Brand products, Denmark). As indicated, irradiated (20 Gy) MSC, adjusted to 10, 1 or 0.1% of the PBL count were added to the wells. Peripheral blood lymphocytes were stimulated with antigen; final concentrations were 10 mg/ml staphylococcal aureus protein A (SpA) (Pharmacia, Uppsala, Sweden), HSV-1/1000 (SMI, Solna, Sweden), VZV 1/1000 (SMI), CMV 0.5 mg/ml (Biosite, Ta¨by, Sweden) and candida mannan (CM) 100 mg/ml (gift from Dr Lena Klingspor, Laboratory of Clinical Bacteriology, Karolinska University Hospital Huddinge, Sweden). [28] [29] [30] The plate was incubated for 6 days.
using a Tomtec harvesting machine (Harvester 96, Tomtec, Orange, CT, USA). Stimulation was defined as proliferation higher than three times the background.
Results
Herpesviral DNA cannot be detected in mesenchymal stem cells from healthy seropositive individuals We investigated the viral serology against CMV, HSV-1, HSV-2, EBV and VZV in 12 healthy MSC donors. Polymerase chain reaction of viral DNA was performed on ex vivo expanded MSC derived from the same donors. Polymerase chain reaction analyses of MSC were negative to all viruses in seropositive and seronegative individuals ( Table 1) . We also performed flow cytometry analysis for surface molecules on the MSC. We chose to analyze CD13, which is reported to be the receptor for CMV and CD21 known as the receptor for EBV. 24, 25 More than 96% of the MSC were positive for CD13 and less than 13% of the MSC were positive for CD21 (Figure 1 ).
Mesenchymal stem cells can be infected with cytomegalovirus and herpes simplex virus type 1 in vitro, but not with Epstein-Barr virus A CPE, indicating viral infection, after 72 h that increased by 144 h was observed when MSC were exposed to CMV (Figure 2) . Titration of supernatants from the CMVexposed cells showed a productive virus infection in MSC, capable of infecting fibroblasts after 48-72 h. Tissue culture infectious dose 50% (TCID 50 ) peaked at 144 h (Table 2 ) (n ¼ 3).
After 24 h incubation of MSC exposed to HSV-1, groups of cells exhibited a typical CPE (Figure 2) . By 72 h all cells in the monolayer showed signs of typical swelling and detached from the wells. Titration of supernatants from HSV-1-exposed MSC extensively infected GMK cells (Table 2) . TCID 50 was maximal after 24 h, and then decreased over time. The CPE increased and was maximal after 144 h (n ¼ 3).
Immunofluorescence analysis was performed on the cells exposed to CMV and HSV-1 seven days post-exposure. Intracellularly located viral antigens were detected in the exposed MSC (n ¼ 3). In the controls, cells incubated in medium alone, no viral antigens were detected. To summarize, the data suggest that MSC can be productively infected with both CMV and HSV-1. The effect of CMV developed more slowly.
We also exposed MSC to EBV and measured the numbers of EBV DNA copies in the MSC. We used P3 cells as a positive control and MSC with no contact to viruses as a negative control. To evaluate the capacity of the P3 solution to infect cells, we successfully infected EBVnegative PBL, confirmed by immunofluorescence against EBV and CD19 ( Figure 3 ). The amount of EBV DNA copies in B lymphocytes on days 3 and 8 was 1122 and 1072, respectively (n ¼ 2). In MSC samples the amount of EBV DNA copies was 36 and 310 on day 3 in two separate experiments and 50 and 200 on day 8. The levels were considerably lower in MSC compared to B lymphocytes despite the same doses of P3 solution. Immunofluorescence was performed on days 3 and 8. Viral antigens could not be visualized in either MSC or the negative control (Figure 3 ). significantly inhibited lymphocyte responses to the above-mentioned infectious agents in a dose-dependent manner. The degree of MSC-induced suppression was similar for all stimuli. Ten percent MSC inhibited proliferation with a mean of 65.172.2% (Po0.001). Inhibition was lower, 33.576.1% (P ¼ 0.005) after addition of 1% MSC and 0.1% MSC reduced proliferation by 18.574.4% (Po0.05).
Mesenchymal stem cells inhibit lymphocyte responses to various infectious agents
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Discussion
In the present study, viruses belonging to the herpesvirus family were not detected by PCR in ex vivo-expanded MSC derived from seropositive individuals. However, human MSC can be infected in vitro by CMV and HSV-1 but not by EBV. Furthermore, lymphocyte proliferation induced by several infectious agents is suppressed in the presence of third-party MSC.
Mesenchymal stem cells have the capacity to differentiate into several tissues including bone, cartilage and fat. [8] [9] [10] [11] They may be used for cell therapy. 22 Mesenchymal stem cells enhance hematopoiesis and co-transplantation of MSC and hematopoietic stem cells may reduce the cytopenic phase. 31 Enhancement of hematopoiesis by MSC has been demonstrated in NOD/SCID mice and fetal sheep. [32] [33] [34] [35] [36] Mesenchymal stem cells are also immunomodulatory and suppress lymphocyte proliferation, prolong skin graft survival and may decrease GvHD. [12] [13] [14] [15] [16] 20 Thus, infusion of MSC to manipulate immune responses is a possible future application in HSCT, organ transplant recipients and in patients with autoimmune disorders, for instance inflammatory bowel disorders. 22 Previous reports indicate that stromal cells, including fibroblasts and hematopoietic precursor cells in the bone marrow, are susceptible to CMV infection. 37 There are differences between properties of MSC and fibroblasts, and no MSC-specific studies have previously been performed to elucidate potential viral side effects of MSC therapy. We therefore wanted to investigate whether there is a possible viral transmission using MSC in transplantation. Presence of CMV was studied in MSC using PCR of the CMV polymerase gene. 38 No CMV DNA was detected with this sensitive method. It is therefore unlikely that ex vivoexpanded MSC, derived from healthy seropositive individuals, carry CMV. No further investigation regarding possible latency was performed. Thus, using healthy donors without symptoms of active disease the risk of transmission of herpesviruses by MSC transplantation should be limited and such individuals can be chosen as MSC donors. However, we do not know if herpesviruses, like CMV and HSV, will be harbored in individuals with an ongoing herpesvirus infection and subsequently transmitted to the MSC recipient. Until this issue has been settled, individuals with an ongoing herpesvirus infection should be avoided for MSC donation.
We investigated MSC with flow cytometry to determine expression of surface molecules that mediate herpesvirus uptake. CD13 is reported as the receptor for CMV. 24 Our results showed that MSC express this receptor. Thereby, MSC should be susceptible for CMV. Moreover, we were able to infect MSC with both CMV and HSV-1 in vitro. The results of the CMV-and HSV-1-infection suggest that MSC are productively infected, that is replication of the virus occurs in the MSC. This is indicated by a raised TCID 50 , when day 1 is compared to several days of incubation. In the HSV-1 experiment the titer declined over time after the peak value of TCID 50 , suggesting inactivation of the virus.
As discussed above, since MSC are susceptible to both CMV and HSV-1 infection in vitro they may be viral transmitters. Mesenchymal stem cells derived from a donor with ongoing viremia could therefore carry herpesvirus. Moreover, herpesviruses frequently reactivate in patients post-HSCT and may cause life-threatening infections. Immunofluorescence against viral proteins (fluorescein isothiocyanate (FITC)) performed on virus-exposed MSC (counterstained red) were positive for CMV (d) and HSV-1 (f), respectively, while virus could not be detected in negative controls (e and g). Reactivation will lead to high viral load in the recipient with subsequent infection of transplanted MSC. Recently, Crapnell and co-workers reported that bone marrow stromal cells are susceptible to CMV. Bone marrow stromal cells infected with CMV were infused into fetal sheep in utero. Although CMV-infected cells were found in several tissues, engraftment was lower compared to transplantation of CMV-negative stromal cells. 39 Thus, transplantation of MSC to a viremic patient may result in low engraftment explained by impaired engraftment capacity of herpesvirus-infected MSC. If herpesviruses hamper engraftment of MSC it will affect the outcome of allogeneic MSC therapy, with poor homing and insufficient effect in intended tissues.
Herpesviruses are also known to infect cells nonpermissively. In the case of CMV it has been shown that a non-permissive infection can become permissive when the viral host cell differentiates. 40 Our in vitro data suggest that CMV and HSV-1 permissively infect MSC. Therefore, the risk of a non-permissive infection in vivo should be low, but the risk cannot be excluded from the in vitro data.
If MSC become herpesvirus infected, that is after viremia or because of high viral load in the recipient, they may spread the infection. Mesenchymal stem cells are known to first home in the lungs according to studies in experimental animals. 41 Infected MSC could theoretically induce CMV interstitial pneumonitis after infusion -a fatal complication in transplant recipients. 3, 6 This is supported by the report from Crapnell et al., implicating widespread CMV infection in different tissues and organs. Similary, if MSC become non-permissively infected in vivo and after transplantation home to tissues and differentiate, they may initiate a disseminating viral infection in various organs. For instance, the use of CMV-infected MSC as treatment of steroid-resistant gastrointestinal GvHD could lead to CMV gastroenteritis. 20 However, none of the seropositive individuals had detectable herpesvirus DNA in their MSC. This may suggest that MSC for allogeneic cell therapies, expanded from healthy seropositive individuals, do not contain infective virus.
In our study, we did not succeed to infect MSC with EBV. To evaluate the infectivity of our EBV solution, PBL were also exposed. Double staining (immunofluorescence) for CD19, a B-lymphocyte marker, and EBV was positive, confirming the infective potential. Our flow cytometry analyses showed that MSC expressed small amounts of CD21 or that a small subpopulation of MSC expressed this surface-antigen receptor which mediates the EBV uptake. Therefore, MSC in general are not susceptible to EBV. Parsons et al. 42 recently described that fetal MSC are susceptible to human herpesvirus 8/Kaposi's sarcomaassociated herpesvirus (HHV8/KSHV) belonging to the same subfamily of gammaherpesvirus as EBV. Mesenchymal stem cells are infected by both cell-free and cell-bound HHV8/KSHV, but supernatants could not transmit infection to naı¨ve cells. Parsons of MSC in the HHV8/KSHV infection -both as a viral reservoir and as modulator of hematopoiesis. Wang et al. 43 showed that HIV-1 infection of stromal cells may suppress the clonogenic potential of MSC and that could help explain the complex pattern of pathogenesis in AIDS. Speculations about HIV-1 infection of MSC beyond the bone marrow were also raised. As mentioned previously, MSC possess immunosuppressive features that may be used in transplantation to reverse GvHD and rejection. 22 However, the immunomodulatory effect may interfere with the immune responses to infections in already immunocompromised transplant recipients. This may lead to severe bacterial, fungal and viral infections. Since CMV can infect MSC, viremia in the recipient may lead to infection of infused MSC and hypothetical suppression of the immunomodulating effects. Clinical trials are needed to elucidate these points.
In summary, our results suggest that MSC can be infected in vitro with both CMV and HSV-1. Mesenchymal stem cells cannot be infected with EBV in vitro, but small amounts or a small subpopulation of MSC expresses CD21, the receptor for its uptake. It is not likely that MSC isolated from healthy seropositive donors contain CMV, HSV-1, HSV-2, EBV or VZV. Therefore, it seems safe to transplant MSC from these individuals to patients in need of MSC. Mesenchymal stem cells also suppress lymphocyte responses to bacteria, fungi and viruses. Whether this affects the outcome of MSC transplantation in patients with ongoing infections needs to be evaluated in clinical trials. Furthermore, the risk to impair immune response to an ongoing infection by MSC treatment should be considered before infusion of MSC to transplant recipients.
